Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 g ethinyl estradiol and 3 mg drospirenone
| العنوان: | Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 g ethinyl estradiol and 3 mg drospirenone |
|---|---|
| المؤلفون: | C J Gruber, T Knudsen, Carlo Bastianelli, A Bjertnaes, Ian Milsom, I Lete, K Rokstad, Martin Birkhäuser, Ingela Lindh, E Aubeny |
| المصدر: | Milsom, I; Lete, I; Bjertnaes, A; Rokstad, K; Lindh, I; Gruber, C J; Birkhäuser, M H; Aubeny, E; Knudsen, T; Bastianelli, C (2006). Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Human reproduction, 21(9), pp. 2304-11. Oxford: Oxford University Press 10.1093/humrep/del162 <http://dx.doi.org/10.1093/humrep/del162Test> |
| بيانات النشر: | Oxford University Press (OUP), 2006. |
| سنة النشر: | 2006 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, medicine.drug_class, Population, Administration, Oral, Ethinyl Estradiol, law.invention, Randomized controlled trial, Oral administration, law, Ethinylestradiol, Breakthrough bleeding, medicine, Humans, education, Menstrual Cycle, Gynecology, education.field_of_study, Desogestrel, business.industry, combined contraceptive vaginal ring/combined oral contraceptive/cycle control/irregular bleeding, Body Weight, Rehabilitation, Contraceptive Devices, Female, Obstetrics and Gynecology, Drospirenone, Confidence interval, Drug Combinations, Reproductive Medicine, Estrogen, Body Composition, Patient Compliance, Androstenes, medicine.symptom, business, Contraceptives, Oral, Intrauterine Devices, medicine.drug |
| الوصف: | BACKGROUND: The objective of this study was to compare cycle control, cycle-related characteristics and bodyweight effects of NuvaRing with those of a combined oral contraceptive (COC) containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. METHODS: A randomized, multicentre, open-label trial in which 983 women were treated (intent-to-treat population) with NuvaRing or the COC for 13 cycles. RESULTS: Breakthrough bleeding or spotting during cycles 2-13 was in general less frequent with NuvaRing than that with the COC (4.7-10.4%) and showed a statistically significant odds ratio of 0.61 (95% confidence interval: 0.46, 0.80) with longitudinal analysis. Intended bleeding was significantly better for all cycles with NuvaRing (55.2-68.5%) than that with the COC (35.6-56.6%) (P < 0.01). Changes from baseline in mean bodyweight and body composition parameters were relatively small for both groups with no notable between-group differences. CONCLUSION: NuvaRing was associated with better cycle control than the COC, and there was no clinically relevant difference between the two groups in bodyweight. |
| وصف الملف: | application/pdf |
| تدمد: | 1460-2350 0268-1161 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb940500d99b54eefa3d8dc3dcd8f6adTest https://doi.org/10.1093/humrep/del162Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....bb940500d99b54eefa3d8dc3dcd8f6ad |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14602350 02681161 |
|---|